How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,088 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Efficacy and Safety of SYN-010 in IBS-C

of study drug if the patient is a sexually active female of child-bearing potential (defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause). Adequate contraceptive measures include: oral contraceptives (stable use for two or more cycles before Screening); intrauterine device; Depo-Provera®; Norplant® System implants; partner with a vasectomy; double

2018 Clinical Trials

122. Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia

by the MINI. Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (e.g. oral contraceptives, intrauterine device, barrier methods, or total abstinence from intercourse; Depo Provera is acceptable if it is started 3 months prior to enrollment). Patients who are a serious suicide or homicide risk, suicidal exclusion criteria as follows: Suicidal ideation associated with actual intent and a method or plan in the past year: "Yes" answers on items 4

2018 Clinical Trials

123. Progestogen-only Injectable contraception

Effectiveness Unit This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. Your download should start automatically. If not . Document types Thinking about taking a qualification? Registration is now quick

2014 Faculty of Sexual & Reproductive Healthcare

125. Depot Medroxyprogesterone Acetate and Bone Effects

medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density. Contraception 2008;77:239–48. Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010;81:281–91. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate (...) . The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008;78:459–64. Pfizer Inc. Depo-provera CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use: highlights of prescribing information. New York (NY): Pfizer; 2012. Available at: . Retrieved February 12, 2014. Hatcher RA, Trussell J, Nelson AL, Cates WJ, Kowal D, Policar MS. Contraceptive technology. 20th ed. New York (NY): Ardent Media; 2012. Cundy T, Ames R

2014 American College of Obstetricians and Gynecologists

126. St Johns Wort and Hormonal Contraception

-druginteractions.org St John’s Wort and Hormonal Contraception 2014 Reference List (1) Faculty of Sexual & Reproductive Health Care. Drug Interactions with Hormonal Contraception. http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf. 2011. (2) Pfizer Limited. Sayana Press:Summary of Product Characteristics. 2013. http://www.medicines.org.uk/emc/medicine/27798/SPC/SAYANA+PRESS+1 04+mg+0.65+ml+suspension+for+injection (3) Pfizer Limited. Depo-Provera 150mg / ml injection. 2012. http (...) ://www.medicines.org.uk/emc/medicine/11121/SPC/Depo- Provera+150mg+ml+Injection/ (accessed 19/03/14) (4) Watts DH, Park JG, Cohn SE, Yu SHJ, Stek A, Clax PA, et al. Safety and Tolerability of DMPA among HIV infected women on antireteroviral therapy. Contrcaeption 2008;72((2)):84-90. (5) Nanda K, Amaral E, Hays M, Viscola MAM, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertility and Sterility 2008;90(4):965-71.

2014 Faculty of Sexual & Reproductive Healthcare

127. Antigone (desogestrel) - Contraception

and its generics and 3 hours for MICROVAL. HAS - Medical, Economic and Public Health Assessment Division 6/12 6.1.2 Other progestogen contraceptives For information, progestogen contraceptives are used parenterally: NEXPLANON 68 mg, implant for subdermal use (etonogestrel): - indication: "Contraception. The safety and efficacy have been established in women between 18 and 40 years of age." - the implant may be left in place for 3 years, - reimbursable proprietary medicinal product. DEPO PROVERA

2014 Haute Autorite de sante

128. Osteoporosis: Prevention and Treatment

. Medications with Risk for Bone Loss or Fracture Definite risk Immunosuppressants • Glucorticoids (systemic >> inhaled a , intranasal, topical, others) • Cyclosporine [Gengraf®, Neoral®, Sandimmune®] • Tacrolimus [Prograf®] • Mycophenolate mofetil [CellCept®] Hormonal and antihormonal agents • Medroxyprogesterone acetate [Depo-Provera®] b • Tamoxifen, before menopause • Aromatase inhibitors (anastrozole/Arimidex®, letrozole/Femara®) • GnRH analogs (leuprolide/Lupron®, goserelin/Zoladex®

2013 University of Michigan Health System

129. Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

be able to read, comprehend, and write at a level sufficient to complete study related materials. Female subjects: Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the Investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intra-uterine device (IUD) intrauterine device/ levonogestrel Intrauterine system (IUS), Depo-Provera(tm

2017 Clinical Trials

130. Maximizing Outcome of Multiple Sclerosis Transplantation

intercourse, (2) consistent use of birth control pills, (3) injectable birth control methods (Depo-provera, Norplant), (4) tubal sterilization or male partner who has undergone vasectomy, (5) placement of an intrauterine device (IUD), or (6) with every act of intercourse, use of diaphragm with contraceptive jelly and/or use of condom with contraceptive foam Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy Forced expiratory volume at one second (FEV1)/ forced

2017 Clinical Trials

131. Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

with subcutaneous insulin by pump at the time of recruitment. Prescription medication regimen stable for > 1 month (except for medications that will not affect the safety of the study and are not expected to affect any outcome of the study, in the judgment of the site PI). Females > 11 years of age must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive

2017 Clinical Trials

132. A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

, e.g., use of oral contraceptives with an additional barrier method (since the study drug may impair the effectiveness of oral contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy, total abstinence, and willing to continue the effective contraception method for 30 days after the last dose of study drug; Ability to understand and provide signed informed consent that fulfills Institutional Review Board's

2017 Clinical Trials

133. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

treatment and for 6 months following the last dose of rucaparib; the following are allowable only: Ongoing use of progesterone-only injectable or implantable contraceptives (eg, Depo Provera, Implanon, Nexplanon) Placement of an intrauterine device or intrauterine system Bilateral tubal occlusion Sterilization, with appropriate post-vasectomy documentation of absence of sperm in ejaculate True, complete (as opposed to periodic) abstinence Exclusion Criteria: Any of the following: Pregnant individuals

2017 Clinical Trials

134. DNA-based Dietary Advice for Adults With Depressive Disorders

prior to the study, and b) they continue on these agents throughout the study. Supplement information will be presented at intake, and the cessation of any such supplements will be required for the participant to continue in screening. Women who are pregnant or breast-feeding; women of childbearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse (for example, intrauterine device, oral contraceptive, implant, Depo-Provera, or barrier devices

2017 Clinical Trials

135. The Effect of Benralizumab on Exercise-induced Bronchoconstriction

; Women of childbearing potential (WOCBP) must use an effective form of birth control (confirmed by the investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device/levonorgestrel Intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™ or Nuvaring™. WOCBP must agree to use effective method of birth control, as defined above, from enrolment

2017 Clinical Trials

136. Contraceptive use among lactating women in Ganta-Afeshum District, Eastern Tigray, Northern Ethiopia, 2015: a cross sectional study. Full Text available with Trip Pro

delivery was 96.5%. The mode of delivery of the participants was spontaneous, instrumental and caesarean section, 95.5%, 2.0%, and 2.5%, respectively. The magnitude of modern contraceptive (MC) utilization was 68.1% (95% CI: 64.4-71.8). The contraceptive method mix was dominated by Depo-Provera (58.8%) followed by implants (31.8%). Almost all the study participants had at least one antenatal care (ANC) visit (99.7%) during the pregnancy of their index child. Participants who had radio and those who

2017 BMC Pregnancy and Childbirth

137. Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety in Patients With Hypoglycemia After Gastric Surgery

; Current administration of oral or parenteral corticosteroids; Pregnancy and/ or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill/patch I vaginal ring, Depo-Provera, Norplant, an intrauterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide

2017 Clinical Trials

138. Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

contraception (eg, abstinence, double barrier method, oral/implantable/transdermal contraception, Depo-Provera, intrauterine device); a woman is of CBP unless she is premenarchal, is at least 2 years postmenopausal, is without a uterus and/or both ovaries, has had a bilateral tubal ligation, or has undergone the Essure procedure with confirmation of tubal blockage. [Note: If a female is identified as less than 2 years postmenopausal, a serum follicle-stimulating hormone (FSH) determination will be performed

2017 Clinical Trials

139. OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

investigational product or investigational medical device within 30 days prior to Screening, or while on study Use or planned use of any injectable drugs containing PEG including medroxyprogesterone (e.g. Depo-Provera) injection within 3 months prior to Screening and while on study Known hypersensitivity to PEG-containing product or any components of OT-58 A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody A history of organ transplantation, chronic immunosuppressive

2017 Clinical Trials

140. Factors associated with contraceptive use in Tigray, North Ethiopia Full Text available with Trip Pro

among 1966 women of reproductive age group (15-49) in 13 districts (3 urban and 10 rural) from May-June 2015. Multistage sampling technique was employed to approach the study participants. Data were analyzed using SPSS version 20. Multiple variable logistic regression analysis was used to identify the effect of independent variables on utilization of contraceptive use.Out of total 1966 women, 1879 (95.6%) have ever heard about family planning. Depo-Provera (depot medroxyprogesterone acetate, or DMPA (...) ) was the most popular contractive method as mentioned by 1757 (93.5%) of the participants. The overall contraceptive prevalence rate among all women was 623 (35.6%) while the contraceptive prevalence rate among married women was 543 (41.0%). Seven-in-ten women had ever used short acting contraceptive. In fact Depo-Provera was the most common type of contraceptive used as mentioned by 402 (64.5%) of the women. The odds of using family planning by married women living in urban areas was two times more than

2017 Reproductive health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>